VINORELBINE TARTRATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1994)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 253GQW851Q
Parent Compound: VINORELBINE

Structure
InChI Key MVHREVCZLKPXGC-DSLGMBOJSA-N
Smile CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C=C(C)CN(C7)c7c6[nH]c6ccccc76)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O
InChI
InChI=1S/C43H50N4O8.C4H6O6/c1-8-40-14-11-16-46-17-15-41(35(40)46)28-19-29(32(52-5)20-31(28)45(4)36(41)43(51,39(50)54-7)37(40)55-25(3)48)42(38(49)53-6)21-26-18-24(2)22-47(23-26)33-27-12-9-10-13-30(27)44-34(33)42;5-1(3(7)8)2(6)4(9)10/h9-14,18-20,26,35-37,44,51H,8,15-17,21-23H2,1-7H3;1-2,5-6H,(H,7,8)(H,9,10)/t26-,35-,36+,37+,40+,41+,42-,43-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C53H66N4O20
Molecular Weight 1079.12
AlogP 4.75
Hydrogen Bond Acceptor 11.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 133.87
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 57.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Tubulin inhibitor PubMed PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma, Non-Hodgkin 3 D008228 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Adenocarcinoma of Lung 3 D000077192 ClinicalTrials
Mesothelioma 3 D008654 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Sarcoma 3 D012509 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Central Nervous System Neoplasms 2 D016543 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Rhabdomyosarcoma, Alveolar 2 D018232 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Neuroblastoma 2 D009447 ClinicalTrials
Breast Neoplasms, Male 2 D018567 ClinicalTrials
Lymphoma, T-Cell, Peripheral 2 D016411 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Colonic Neoplasms 2 D003110 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials
Endometrial Neoplasms 1 D016889 ClinicalTrials
Vaginal Neoplasms 1 D014625 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.35
Gastrointestinal disorders
9.37
Injury, poisoning and procedural complications
7.86
Blood and lymphatic system disorders
7.8
Nervous system disorders
7.25
Respiratory, thoracic and mediastinal disorders
6.94
Vascular disorders
5.84
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
5.7
Skin and subcutaneous tissue disorders
5.17
Investigations
5.06
Cardiac disorders
5.04
Infections and infestations
4.33
Metabolism and nutrition disorders
3.19
Musculoskeletal and connective tissue disorders
2.86
Immune system disorders
2.1
Renal and urinary disorders
2.02

Cross References

Resources Reference
ChEMBL CHEMBL538943
EPA CompTox DTXSID5047825
FDA SRS 253GQW851Q
PubChem 11607738
SureChEMBL SCHEMBL4764
CONTENTS